Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective.

Cell therapy using mesenchymal stromal cells (MSCs) is a promising new avenue of treatment for critical limb ischemia (CLI). Preclinical studies have suggested that MSCs enhance neovascularization in ischemic limbs. In this commentary, we discuss a recent study by Gupta and colleagues, one of the first human trials using allogeneic MSCs for CLI, in relation to the current state of knowledge regarding cell therapy for CLI.

Recently, Gupta and colleagues [1] reported the results of a randomized double-blind placebo-controlled phase I/II study on the efficacy and safety of allogeneic mesenchymal stromal cells (MSCs), administered by intramuscular injection in patients with critical limb ischemia (CLI). Because the number of randomized controlled trials investigating stem cell therapy in peripheral arterial disease (PAD) is limited, this study is a welcome addition. Gupta and colleagues are also one of the first groups to apply MSCs in PAD.

Roughly a dozen clinical trials investigating stem or progenitor cell therapy in patients with CLI have been reported, but many were of limited size and not placebo-controlled [2]. In most studies, the cell therapy product under investigation consisted of autologous bone marrow mononuclear cells (BMCs), which is a heterogeneous mixture of cells obtained by density gradient centrifugation of bone marrow aspirate. Infusion of BMCs has been reported to lead to improvements in ankle-brachial index (ABI) and pain-free walking distance. However, the quality of evidence for efficacy is limited, as most studies lacked a proper placebo or sham group for the invasive bone marrow-harvesting procedure that is required for a study investigating autologous material.

Advances in good manufacturing practice-compliant production of more sophisticated cell products are now opening up the way to a second generation of cell therapy trials. MSCs, which are obtained by expansion of adherent bone marrow cells in ex vivo culture, have the capacity to enhance neovascularization and are a promising candidate for cell therapy in CLI. Owing to their inherent low antigenicity, MSCs may be administered in allogeneic recipients [3]. Although allogeneic administration has been shown to be safe [4], eventual immunization may occur upon differentiation of residual injected cells [5]. Because the pro-angiogenic effects of MSCs occur relatively quickly after administration [6], delayed immunization does not appear to be an obstacle when MSCs are given as a single-time administration. In advanced arterial occlusive disease, as in CLI, it may preferable to give multiple doses, especially considering the relative ease of administration and the lack of an acute indication. It remains to be elucidated whether allogeneic MSCs are sufficiently immunoprivileged to prevent alloimmunization if they are administered repeatedly in a ‘vaccination scheme’.

Animal [7] and human [8] studies comparing efficacy of BMCs and MSCs in ischemic limbs suggest that MSCs are superior to BMCs in promoting neovascularization. The study by Gupta and colleagues, though designed primarily to assess safety and feasibility, shows a substantial improvement in ABI. To illustrate the treatment effect in relation to other studies, we have added a meta-analytic scatterplot plot showing ABI increases after cell therapy observed by Gupta and colleagues and three prior [8-10] placebo-controlled studies that report the same outcome measure (Figure 1).

Figure 1

Improvements in ankle-brachial index (ABI) after cell therapy. Meta-analytic scatterplot with meta-regression lines shows improvements in ABI compared with baseline after injection of a cell-therapy product or placebo. The two bone marrow mononuclear cell (BMC) cohorts in the study by Tateishi-Yuyama and colleagues [9] were included separately. Regression lines were fit with a mixed model using REML (restricted maximum likelihood) estimation; bands show 95% confidence intervals. This figure was prepared with the ‘metafor’ [11] package in ‘R’. MSC, mesenchymal stromal cell.

Gupta and colleagues are to be commended for including a placebo arm in their study, as the invasiveness of cell injections often prevents researchers from including controls in early-phase clinical studies. Unfortunately, it is not entirely clear how blinding in this study was performed for either patients or treating physicians or whether blinding was successfully maintained throughout the study. For instance, the placebo administered by the authors is a balanced crystalloid solution that is likely to be easily distinguished from the serum-containing (and potentially dimethylsulfoxide-containing) cryopreservation medium in which the cell product was suspended. A rigorously blind study design is essential to exclude confounding factors, which may lead to an overestimation of treatment effects [12].

Another consideration in the interpretation of the findings reported by Gupta and colleagues is that the study population consists of both patients with an arteriosclerotic disease etiology and patients with thromboangitis obliterans, but the authors do not report in which proportions. In previous studies, it has been shown that disease etiology is an important determinant of treatment success [13], which makes this omission somewhat unfortunate.

The mechanism of action behind MSC-mediated improvements in perfusion is, at present, still poorly understood. MSC tracing studies in animal models show that MSCs are retained for only a short period of time in injected limbs [6,14] and that incorporation into the vascular bed does not contribute to the observed pro-angiogenic effects [6]. Rather, MSCs are thought to act through paracrine effects, either directly on the local endothelium [15] or indirectly through the recruitment of angiogenic monocytes [14]. These functions are likely to be unrelated to the multipotent capability of MSCs, and it is unclear whether using whole cells has an added functional benefit (for example, through homing) above their secreted growth factors [16]. There is even considerable discussion whether cell therapy with MSCs deserves the epithet of stem cell therapy at all [17]. Regardless of these considerations, the studies by Gupta and colleagues and others show that further development of MSC therapy is, at the very least, a promising avenue in the treatment of patients with very few other options.

Abbreviations

ABI: Ankle-brachial index; BMC: Bone marrow mononuclear cell; CLI: Critical limb ischemia; MSC: Mesenchymal stromal cell; PAD: Peripheral arterial disease.

Competing interests

The authors declare that they have no competing interests.